Effects of radiation therapy on oesophageal transit in patients with inner quadrant breast tumour

Türkölmez, Şeyda; Atasever, Tamer; Muge, Akmansu

doi:10.1097/01.mnm.0000171785.03403.6f

Cited by 9 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Esophageal motility was evaluated before and immediately after RT using esophageal scintigraphy. Post-irradiation therapy ETT values were significicantly higher compared to pre-radiation therapy ETT values (p<0.001) (Turkolmez et al, 2005). These results confirm the results of our study.…”

Section: 53 Oral Glutamine Supplementation For Esophagitis In Lung Csupporting

confidence: 82%

“…The presence of these symptoms, which are clinical manifestations of dyskinesia and mucositis respectively, suggests that radiation induced acute esophagitis might be associated with altered organ motillity (Sasso et al, 2008). A variety of studies have shown that irradiation of the esophagus causes early mucosal changes and acute effects on esophageal motility or transit (Turkolmez et al, 2005;Sasso et al, 2008). Clinical and dosimetric factors may be related to the incidence and severity of acute radiation esophagitis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Glutamine Supplementation Reduces Radiotherapy-induced Esophagitis in Lung Cancer Patients

Kanyılmaz¹,

Muge²,

A³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of this study was to assess the the efficacy of oral glutamine (GLN) in prevention of acute radiation-induced esophagitis in patients with lung cancer and determine the predictive role of clinical and dosimetric parameters. Materials and Methods: Thirty-two patients diagnosed with lung cancer were studied prospectively. Sixteen patients (50%) received prophylactic powdered GLN orally in doses of 10g/8h. Patients were treated 2 Gy per fraction daily, 5 days a week. We evaluated the grading of esophagitis daily at the end of each fraction of each treatment day until a cumulative dose of 50 Gy was reached. The primary end point was radiation-induced esophagitis. Results: All patients tolerated GLN well. Toxicity grade, weight loss, serum cytokine levels and esophageal transit times exhibited statistically significant improvement in the GLN receiving group. GLN suppressed the inflammation related to the disease and treatment and reduced toxicity with statistical significance. Conclusions: This study suggests a benefical role of oral GLN use in prevention and/or delay of radiation-induced esophagitis, in terms of esophageal transit time and serum immunological parameters, as well as weight loss.

show abstract

Section: 53 Oral Glutamine Supplementation For Esophagitis In Lung Csupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Oral Glutamine Supplementation Reduces Radiotherapy-induced Esophagitis in Lung Cancer Patients

Kanyılmaz¹,

Muge²,

A³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Acute radiation esophagitis often lead to dysphagia and odynophagia due to mucosal changes and effects on esophageal motility . [18,19] ARIE was not only related to body weight loss, poor nutrition, and poor quality of life but also decreased the effective treatment dose of radiotherapy, increased unplanned treatment course delay, causing decreased tumor control and survival rate . [20] Late radiation-induced esophagitis usually refer to onset more than 3 months after the completion of thoracic irradiation.…”

Section: Discussionmentioning

confidence: 99%

Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer

Chang

Lai

Hung³

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: Complications related to concurrent chemoradiotherapy (CCRT) such as acute radiation-induced esophagitis (ARIE) may cause significant morbidity and unplanned treatment delays in patients with advanced non-small cell lung cancer (NSCLC). We designed a prospective randomized study to assess the impact of glutamine (GLN) supplementation in preventing CCRT-induced toxicities of advanced NSCLC patients. Methods: From September 2014 to September 2015, 60 patients diagnosed with NSCLC were included to the study. Thirty patients (50%) received prophylactic powdered GLN orally at a dose of 10 g/8 h. The prescribed radiation dose to the planning target volume was 30 Gy in 2-Gy fractions. The endpoints were radiation-induced esophagitis, mucositis, body weight loss, overall survival and progression-free survival. Results: The 60 patients with NSCLC included 42 men and 18 women with a mean age ± standard deviation of 60.3 years ± 18.2 (range, 44–78 years). At a median follow-up of 26.4 months (range 10.4–32.2), all patients tolerated GLN well. A administration of GLN was associated with a decrease in the incidence of grade 2 or 3 ARIE (6.7% vs 53.4% for Gln+ vs Gln-; P = .004). GLN supplementation appeared to significantly delay ARIE onset for 5.8 days (18.2 days vs 12.4 days; P = .027) and reduced incidence of weight loss (20% vs 73.3%; P = .01). Discussion: Our study suggests a beneficial effect of oral glutamine supplementation for the prevention from radiation-induced injury and body weight loss in advanced NSCLC patients who receiving CCRT.

show abstract

“…23 Radiotherapy increases the ETT in 80% of patients, even at low doses. 21,24 No data are available on the ETT at higher doses or with CCRT, but most likely the severity and incidence of increased ETT will be higher. It is unknown when and if the esophageal motility returns to normal after CCRT.…”

Section: Smoking Cessationmentioning

confidence: 99%

Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer

et al. 2020

View full text Add to dashboard Cite

Concurrent chemotherapy and radiotherapy (CCRT) followed by durvalumab immune therapy in appropriate patients is considered to be the standard of care in most fit stage III non-small-cell lung cancer (NSCLC) patients. However, CCRT is a toxic treatment that affects all organ systems and may cause acute and permanent side effects, some of which may be lethal. Supportive care is therefore of utmost importance in this clinical setting. A group of experts from the European Society for Therapeutic Radiology and Oncology (ESTRO) and the European Society of Medical Oncology (ESMO) identified the following items of importance for further improvement of supportive care: smoking cessation; nutrition before and during CCRT (including treatment and prevention of anorexia); physical exercise before and during CCRT; prevention and treatment of acute esophagitis and dysphagia; treatment of cough and dyspnea; treatment of skin reactions; treatment of fatigue; prophylaxis of nausea and emesis; prevention, diagnosis, and treatment of cardiac disease and damage; and optimization of radiotherapy techniques and chemotherapy adjustments to reduce toxicity in the era of immune therapy. The resulting recommendations are summarized in this manuscript and knowledge gaps identified, in which future investments are needed to improve supportive care and hence quality of life and survival for our stage III NSCLC patients.

show abstract

Effects of radiation therapy on oesophageal transit in patients with inner quadrant breast tumour

Abstract: Oesophageal transit seems to be affected by radiation even without a clinically significant oesophageal symptom and oesophageal scintigraphy allows sensitive, non-invasive and quantifiable assessment of the oesophageal transit time.

Cited by 9 publications

References 27 publications

Oral Glutamine Supplementation Reduces Radiotherapy-induced Esophagitis in Lung Cancer Patients

Oral Glutamine Supplementation Reduces Radiotherapy-induced Esophagitis in Lung Cancer Patients

Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer

Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer

Contact Info

Product

Resources

About